Obesity in people living with type 1 diabetes.
Adolescent
Bariatric Surgery
Behavior Therapy
Body Composition
/ drug effects
Child
Child, Preschool
Diabetes Mellitus, Type 1
/ complications
Female
Humans
Hyperinsulinism
/ chemically induced
Infant
Insulin
/ adverse effects
Life Style
Male
Obesity
/ complications
Overweight
/ complications
Weight Gain
/ drug effects
Young Adult
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
08
05
2021
revised:
26
08
2021
accepted:
31
08
2021
pubmed:
4
10
2021
medline:
4
11
2021
entrez:
3
10
2021
Statut:
ppublish
Résumé
Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hyperinsulinaemia, insulin profiles that do not match basal and mealtime insulin needs, defensive snacking to avoid hypoglycaemia, or a combination of these, are believed to affect body composition and drive excessive accumulation of body fat in people with type 1 diabetes. The consequences of overweight or obesity in people with type 1 diabetes are of particular concern, as they increase the risk of both diabetes-related and obesity-related complications, including cardiovascular disease, stroke, and various types of cancer. In this Review, we summarise the current understanding of the aetiology and consequences of excessive bodyweight in people with type 1 diabetes and highlight the need to optimise future prevention and treatment strategies in this population.
Identifiants
pubmed: 34600607
pii: S2213-8587(21)00246-1
doi: 10.1016/S2213-8587(21)00246-1
pii:
doi:
Substances chimiques
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-785Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests CM reports consulting fees from Novo Nordisk, Sanofi, Merck Sharp & Dohme, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Insulet, and Zealand Pharma; and serves or has served on the speaker bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Novartis. RNF reports personal fees from Novo Nordisk, Sanofi, Abbott, and Medtronic; participation on an advisory board for Novo Nordisk, Sanofi, and Abbott; holds a fiduciary role in international relations for Sociedad Mexicana de Nutricion y Endocrinologa (SMNE); and has received product from Novo Nordisk, Sanofi, Abbott, Medtronic, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, and Pfizer. All other authors declare no competing interests.